Literature DB >> 8898462

Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya.

W G Jaoko1, G Muchemi, F O Oguya.   

Abstract

Four hundred and thirty six pupils in two primary schools in Kibwezi, Kenya aged between seven and sixteen years and positive for S. mansoni were treated as follows: 320 pupils with a single dose of praziquantel at 40 mg/kg body weight and 116 controls with a placebo. Immediate and delayed side effects of praziquantel were observed. The main side-effects were abdominal pain (36.3%), headache (35.3%) and nausea (13.1%). There was correlation between frequencies of these side-effects and intensity of infection measured as eggs per gram of faeces. Other side-effects included dizziness (9.7%), fever (7.8%), urticaria and bloody diarrhoea. Overall, the side-effects of praziquantel were mild and transient, and did not require any intervention. For ethical reasons, all pupils who served as controls were treated with praziquantel after the study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898462

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  8 in total

1.  Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease.

Authors:  Lucía Alvela-Suárez; Virginia Velasco-Tirado; Moncef Belhassen-Garcia; Ignacio Novo-Veleiro; Javier Pardo-Lledías; Angela Romero-Alegría; Luis Pérez del Villar; María Paz Valverde-Merino; Miguel Cordero-Sánchez
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

Review 2.  Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials.

Authors:  Julien Zwang; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

Review 3.  Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.

Authors:  Julien Zwang; Piero Olliaro
Journal:  Parasit Vectors       Date:  2017-01-26       Impact factor: 3.876

4.  Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome.

Authors:  Pierre H H Schneeberger; Jean T Coulibaly; Gordana Panic; Claudia Daubenberger; Morgan Gueuning; Jürg E Frey; Jennifer Keiser
Journal:  Parasit Vectors       Date:  2018-03-12       Impact factor: 3.876

5.  Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data.

Authors:  Martin Walker; Luzia T Freitas; Julia B Halder; Matthew Brack; Jennifer Keiser; Charles H King; Bruno Levecke; Yvonne Ai-Lian Lim; Otavio Pieri; Doudou Sow; J Russell Stothard; Joanne P Webster; Xiao-Nong Zhou; Robert F Terry; Philippe J Guérin; Maria-Gloria Basáñez
Journal:  Wellcome Open Res       Date:  2022-01-05

6.  Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana.

Authors:  Wisdom Akrasi; Augustine Suurinobah Brah; Mainprice Akuoko Essuman; Viona Osei; Alex Boye
Journal:  PLoS Negl Trop Dis       Date:  2022-09-12

7.  Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children.

Authors:  Mahamadou S Sissoko; Abdoulaye Dabo; Hamidou Traoré; Mouctar Diallo; Boubacar Traoré; Drissa Konaté; Boubacar Niaré; Moussa Diakité; Bourama Kamaté; Abdrahamane Traoré; Aboudramane Bathily; Amadou Tapily; Ousmane B Touré; Sarah Cauwenbergh; Herwig F Jansen; Ogobara K Doumbo
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

8.  A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya.

Authors:  Sammy M Njenga; Paul M Ng'ang'a; Mariam T Mwanje; Fatuma S Bendera; Moses J Bockarie
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.